Vito Fanelli1, Yasumasa Morita, Paola Cappello, Mirna Ghazarian, Bina Sugumar, Luisa Delsedime, Jane Batt, V Marco Ranieri, Haibo Zhang, Arthur S Slutsky. 1. From the Department of Anesthesia and Critical Care, University of Turin, AOU Città della Salute e della Scienza di Torino - Ospedale Molinette, Torino, Italy (V.F., V.M.R.); Critical Care Program, The Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, Ontario, Canada (Y.M., M.G., B.S., J.B., H.Z., A.S.S.); Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy (P.C.); Department of Pathology, AOU Città della Salute e della Scienza di Torino - Ospedale Molinette, Torino, Italy (L.D.); Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada (H.Z., A.S.S.); and Departments of Anesthesia and Physiology, University of Toronto, Toronto, Ontario, Canada (H.Z.).
Abstract
BACKGROUND: Neuromuscular blocking agents (NMBAs) bind the nicotinic acetylcholine receptor α1 (nAChRα1) that also contributes to inflammatory signaling. Thus, the author hypothesized that the use of NMBA mitigates lung injury by improving ventilator synchrony and decreasing inflammatory responses. METHODS: Lung injury was induced by intratracheal instillation of hydrogen chloride in rats that were randomized to receive no NMBA with evidence of asynchronous ventilation (noNMBA/aSYNC, n = 10); no NMBA with synchronous ventilation (noNMBA/SYNC, n = 10); cisatracurium (CIS, n = 10); or pancuronium (PAN, n = 10). Mechanical ventilation was set at a tidal volume of 6 ml/kg and positive end-expiratory pressure 8 cm H2O for 3 h. Human lung epithelial, endothelial, and CD14⁺ cells were challenged with mechanical stretch, lipopolysaccharide, lung lavage fluids (bronchoalveolar lavage fluid), or plasma obtained from patients (n = 5) with acute respiratory distress syndrome, in the presence or absence of CIS or small-interfering RNA and small hairpin RNA to attenuate the cell expression of nAChRα1. RESULTS: The use of CIS and PAN improved respiratory compliance (7.2 ± 0.7 in noNMBA/aSYNC, 6.6 ± 0.5 in noNMBA/SYNC, 5.9 ± 0.3 in CIS, and 5.8 ± 0.4 cm H2O/l in PAN; P < 0.05), increased PaO2 (140 ± 54, 209 ± 46, 269 ± 31, and 269 ± 54 mmHg, respectively, P < 0.05), and decreased the plasma levels of tumor necrosis factor-α (509 ± 252 in noNMBA, 200 ± 74 in CIS, and 175 ± 84 pg/ml in PAN; P < 0.05) and interleukin-6 (5789 ± 79, 1608 ± 534, and 2290 ± 315 pg/ml, respectively; P < 0.05). The use of CIS and PAN or silencing the receptor nAChRα1 resulted in decreased cytokine release in the human cells in response to a variety of stimuli mentioned earlier. CONCLUSIONS: The use of NMBA is lung protective through its antiinflammatory properties by blocking the nAChRα1.
BACKGROUND: Neuromuscular blocking agents (NMBAs) bind the nicotinic acetylcholine receptor α1 (nAChRα1) that also contributes to inflammatory signaling. Thus, the author hypothesized that the use of NMBA mitigates lung injury by improving ventilator synchrony and decreasing inflammatory responses. METHODS:Lung injury was induced by intratracheal instillation of hydrogen chloride in rats that were randomized to receive no NMBA with evidence of asynchronous ventilation (noNMBA/aSYNC, n = 10); no NMBA with synchronous ventilation (noNMBA/SYNC, n = 10); cisatracurium (CIS, n = 10); or pancuronium (PAN, n = 10). Mechanical ventilation was set at a tidal volume of 6 ml/kg and positive end-expiratory pressure 8 cm H2O for 3 h. Human lung epithelial, endothelial, and CD14⁺ cells were challenged with mechanical stretch, lipopolysaccharide, lung lavage fluids (bronchoalveolar lavage fluid), or plasma obtained from patients (n = 5) with acute respiratory distress syndrome, in the presence or absence of CIS or small-interfering RNA and small hairpin RNA to attenuate the cell expression of nAChRα1. RESULTS: The use of CIS and PAN improved respiratory compliance (7.2 ± 0.7 in noNMBA/aSYNC, 6.6 ± 0.5 in noNMBA/SYNC, 5.9 ± 0.3 in CIS, and 5.8 ± 0.4 cm H2O/l in PAN; P < 0.05), increased PaO2 (140 ± 54, 209 ± 46, 269 ± 31, and 269 ± 54 mmHg, respectively, P < 0.05), and decreased the plasma levels of tumor necrosis factor-α (509 ± 252 in noNMBA, 200 ± 74 in CIS, and 175 ± 84 pg/ml in PAN; P < 0.05) and interleukin-6 (5789 ± 79, 1608 ± 534, and 2290 ± 315 pg/ml, respectively; P < 0.05). The use of CIS and PAN or silencing the receptor nAChRα1 resulted in decreased cytokine release in the human cells in response to a variety of stimuli mentioned earlier. CONCLUSIONS: The use of NMBA is lung protective through its antiinflammatory properties by blocking the nAChRα1.
Authors: Christophe Guervilly; Magali Bisbal; Jean Marie Forel; Malika Mechati; Samuel Lehingue; Jeremy Bourenne; Gilles Perrin; Romain Rambaud; Melanie Adda; Sami Hraiech; Elisa Marchi; Antoine Roch; Marc Gainnier; Laurent Papazian Journal: Intensive Care Med Date: 2016-12-24 Impact factor: 17.440
Authors: Jeremy R Beitler; Scott A Sands; Stephen H Loring; Robert L Owens; Atul Malhotra; Roger G Spragg; Michael A Matthay; B Taylor Thompson; Daniel Talmor Journal: Intensive Care Med Date: 2016-06-24 Impact factor: 17.440
Authors: Sami Hraiech; Jean-Marie Forel; Christophe Guervilly; Romain Rambaud; Samuel Lehingue; Mélanie Adda; Pierre Sylla; Sabine Valera; Julien Carvelli; Marc Gainnier; Laurent Papazian; Jérémy Bourenne Journal: Ann Intensive Care Date: 2017-08-02 Impact factor: 6.925
Authors: Davide Chiumello; Laurent Brochard; John J Marini; Arthur S Slutsky; Jordi Mancebo; V Marco Ranieri; B Taylor Thompson; Laurent Papazian; Marcus J Schultz; Marcelo Amato; Luciano Gattinoni; Alain Mercat; Antonio Pesenti; Daniel Talmor; Jean-Louis Vincent Journal: Crit Care Date: 2017-09-12 Impact factor: 9.097